AstraZeneca PLC (AZN) Stock

NASDAQ

HealthcareDrug Manufacturers - General Website

AZN has an Alpha Score of 42 out of 100 (weak), computed on Oct 26, 2026 from 3 of 4 sub-scores. 19 members of Congress disclosed 36 trades in AZN since 2014: 18 purchases and 17 sales, most recently Alan Armstrong (purchase, Mar 31, 2026). Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 25.3 and its net margin 17.0% (key statistics as of Oct 29, 2026).

$186.65

+7.02%

Last price 2026-10-30 20:00 UTC

Source: Finnhub

Alpha Score

Weak

Signal SnapshotMarket signals →

Alpha Score

42 · Weak

Alpha Score of 42 reflects weak overall profile with weak momentum, weak value, moderate quality. Based...

Computed Oct 26, 2026

Congress

36 trades · 19 members

Latest: Alan Armstrong, purchase on Mar 31, 2026.

STOCK Act disclosures

Insider Activity

+$3K net

1 buys and 0 sells in the 90 days to Oct 30, 2026.

Form 4 · last trade Aug 8, 2026

What is AZN's Alpha Score?

How it works →

Alpha Score of 42 reflects weak overall profile with weak momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum

Poor

Value

Weak

Quality

Moderate

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Oct 26, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded AstraZeneca PLC (AZN)?

Members

Disclosed trades

Purchases

Sales

Most recent: Alan Armstrong (purchase, Mar 31, 2026); records start Apr 25, 2014.

Politician	Trade date	Type	Amount
Alan Armstrong R-OK · Senate	2026-03-31	purchase	$1k – $15k
Alan Armstrong R-OK · Senate	2026-03-30	purchase	$15k – $50k
Gil Cisneros D-CA · House	2025-12-18	purchase	$1k – $15k
Julia Letlow R-LA · House	2025-12-08	purchase	$1k – $15k
Gil Cisneros D-CA · House	2025-11-19	purchase	$1k – $15k
Lisa McClain R-MI · House	2025-10-31	sale	$1k – $15k
Lisa McClain R-MI · House	2025-10-30	purchase	$1k – $15k
Lisa McClain R-MI · House	2025-10-30	sale	$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.

Every member of Congress who traded AZN, with filing lags →

Are AstraZeneca PLC insiders buying or selling?

SEC Form 4 filings

90 days to Oct 30, 2026

Buys

Sells

Net $

+$3K

Unique insiders

Date	Insider	Role	Type	Shares	Value
Aug 8, 26	Sharma Mani	See Remarks	BUY	20.233	$3K

SEC Form 4 filings as of Oct 30, 2026

See cluster-buy signals across all tickers →

What are AZN's key statistics?

P/E Ratio

25.27

EPS (TTM)

6.69

Dividend Yield

2.30%

Beta

1.28

Net Margin

17.02%

ROE

21.74%

Debt / Equity

0.61

52W High

$15730.00

52W Low

$11404.00

Key statistics as of Oct 29, 2026

How does AZN's valuation compare with the Healthcare sector?

Metric	AZN	Healthcare median	Companies in median
P/E ratio	25.3	27.1	97
Net margin	17.02%	5.48%	139
Return on equity	21.74%	6.84%	158
Dividend yield (payers)	2.30%	1.62%	50

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.

What moved AZN recently?

AI-written from the data on this page

AstraZeneca slips 1.15% as healthcare sector weighs

Oct 28, 2026

AstraZeneca closed at $170.08 on Oct. 27, down 1.15% on the session. The stock trades near the upper end of its 52-week range of $114.04–$157.30, with a P/E of 24.56 and EPS of $6.69. Revenue grew 8.6% year over year, while EPS jumped 25.9%, supported by a net margin of 17.0%. The Alpha Score of 42.4 reflects a quality sub-score of 66.4, offset by weaker momentum (32.6) and value (45.2). No company-specific catalyst drove the decline; the move tracked broader healthcare weakness. Investors will watch for upcoming quarterly results and any pipeline updates that could shift the momentum component of the score.

AZN price chart

What does AstraZeneca PLC do?

AstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a multinational biopharmaceutical company headquartered in Cambridge, United Kingdom. The company focuses on the discovery, development, manufacture, and commercialization of prescription medicines across key therapeutic areas. Oncology constitutes its largest segment, featuring products like Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap. Other core areas include cardiovascular, renal, and metabolic medicines such as Farxiga and Brilinta; rare disease therapies like Ultomiris and Soliris; and respiratory and immunology treatments including Symbicort, Fasenra, and Breztri. AstraZeneca PLC also offers vaccines and immune therapies. It serves primary and specialty care physicians globally through distributors and local offices, with significant presence in the United States, Europe, and Asia. This structure positions AstraZeneca PLC as a major player in the global pharmaceutical industry, addressing diverse medical needs in oncology, rare diseases, and chronic conditions.

CEO

Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.

Employees

96,100

Market Cap

$198.86B

Ask about AZNAI research agent

Quick Facts

ExchangeNASDAQ

SectorHealthcare

IndustryDrug Manufacturers - General

Market Cap$198.86B